Board of Directors and Shareholder update

ConvaTec Group PLC
08 September 2023
 

This announcement contains inside information

 

Board of Directors and Shareholder update

 

Convatec Group PLC (the 'Company') announces that it has agreed, with Novo Holdings A/S, to end the relationship agreement entered into when Novo Holdings acquired their stake in the Company. Consequently, Sten Scheibye will be stepping down from the Board.  These changes will take effect from today.

 

Novo Holdings said "Given the increasing momentum in Convatec's growth and margin trajectory and the high regard and confidence we have in management, we no longer feel a need to occupy a board position at the Company. As shareholders, we are very excited by the opportunity we see for further value creation by the Company."

 

Commenting on behalf of the Board, the Chairman John McAdam said "Sten has been a valued member of the Board over the last five years and on behalf of the Group I would like to extend our thanks for his contribution and insights. Novo Holdings remains an important shareholder in Convatec and we look forward to continuing our relationship and dialogue."

 

Sten Scheibye commented "I have very much enjoyed my time on Convatec's Board.  The Group has a clear strategy and strong management team.  I have no doubt that the Company will continue to make significant progress in the future."

 

The person responsible for making this announcement is Robyn Butler-Mason, Company Secretary.

 

LEI Code:

 213800LS272L4FIDOH92

 

Contacts

Analysts & Investors

Kate Postans, Vice President of Investor Relations & Corporate Communications

Sheebani Chothani, Investor Relations & Corporate Communications Manager

+44 (0) 7826 447807


+44 (0) 7805 011046                           

ir@convatec.com

Media

Buchanan: Charles Ryland / Chris Lane 

+44 (0)207 466 5000

 

About Convatec

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in advanced wound care, ostomy care, continence care and infusion care. With around 10,000 colleagues, we provide our products and services in almost 100 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin, to improved patient outcomes and reduced care costs. Group revenues in 2022 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more about Convatec, please visit http://www.convatecgroup.com

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings